Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
5.82M
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
167K
-
Shares change
-
+41K
-
Total reported value, excl. options
-
$101K
-
Value change
-
+$22K
-
Number of buys
-
8
-
Number of sells
-
-3
-
Price
-
$0.60
Significant Holders of NovaBay Pharmaceuticals, Inc. - Common Stock, par value $0.01 per share (NBY) as of Q4 2024
16 filings reported holding NBY - NovaBay Pharmaceuticals, Inc. - Common Stock, par value $0.01 per share as of Q4 2024.
NovaBay Pharmaceuticals, Inc. - Common Stock, par value $0.01 per share (NBY) has 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 167K shares
of 5.82M outstanding shares and own 2.87% of the company stock.
Largest 10 shareholders include C2C Wealth Management, LLC (50.9K shares), GEODE CAPITAL MANAGEMENT, LLC (33K shares), TWO SIGMA SECURITIES, LLC (31.4K shares), Virtu Financial LLC (27.7K shares), XTX Topco Ltd (16.1K shares), Tower Research Capital LLC (TRC) (5.45K shares), MORGAN STANLEY (2.04K shares), JPMORGAN CHASE & CO (239 shares), SBI Securities Co., Ltd. (50 shares), and BANK OF AMERICA CORP /DE/ (42 shares).
This table shows the top 14 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.